AOD-9604 + Tesamorelin Stack

1. The two fat compartments: visceral and subcutaneous

Body fat is not one thing. The two compartments that matter for this conversation behave differently, sit in different places, and carry different health implications.

• Subcutaneous fat is the layer directly under the skin. It is the fat you can pinch at the waist, hips, and thighs. It is largely a storage and insulation tissue and is metabolically less dangerous than its deeper counterpart.
• Visceral fat (also called visceral adipose tissue, or VAT) is packed deep in the abdomen, wrapped around the liver, intestines, and other organs. It is metabolically active and is the compartment most strongly linked to insulin resistance, elevated triglycerides, and cardiometabolic risk.

This split is the whole reason a two-peptide stack is even discussed. A person with a high waist measurement may be carrying excess in both compartments, and the compartments do not always shrink in parallel. The pitch behind pairing tesamorelin with AOD-9604 is that you assign one molecule to each compartment. As the rest of this guide makes clear, that pitch is cleaner in theory than the evidence is in practice.

2. Tesamorelin: the visceral fat peptide

Tesamorelin is a stabilized GHRH analog. It is the same native growth hormone-releasing hormone molecule with a chemical modification that extends its half-life, and it signals your own pituitary to release pulses of natural growth hormone rather than supplying synthetic HGH. It is one of the very few peptides in this category with genuine Phase III human trial data and an FDA approval (as Egrifta, for HIV-associated lipodystrophy).

According to PubMed, a pooled analysis of two multicenter, double-blind, placebo-controlled Phase III trials (Falutz et al., J Clin Endocrinol Metab, 2010) randomized 806 antiretroviral-treated HIV patients with excess abdominal fat to tesamorelin 2 mg subcutaneously daily or placebo. At 26 weeks, the tesamorelin group showed a 15.4 percent treatment effect for visceral adipose tissue reduction, with no clinically significant change in subcutaneous abdominal fat and a significant rise in IGF-1, and the drug was generally well tolerated without clinically meaningful changes in glucose parameters (DOI).

A 52-week extension (Falutz et al., AIDS, 2008) found the VAT reduction was sustained at roughly 18 percent over a year of continuous treatment, but also that the visceral fat re-accumulated once treatment stopped (DOI). That detail matters: tesamorelin manages visceral fat while you take it, rather than resetting it.

The honest caveat: every one of those trials was run in people with HIV-associated lipodystrophy. There is no large dedicated trial of tesamorelin for general visceral fat in people without HIV. Off-label use rests on the assumption that the GHRH mechanism behaves the same way in other populations, which is plausible but not proven. That is the most important limitation to carry into this entire stack discussion.

→ Deeper reads: Tesamorelin buyer's guide | Tesamorelin protocol guide

3. AOD-9604: the subcutaneous lipolysis fragment

AOD-9604 is a synthetic fragment of human growth hormone, corresponding to amino acids 176 to 191 at the molecule's C-terminus. The theory is that it isolates growth hormone's fat-burning (lipolytic) action while leaving out the parts of the molecule that affect blood sugar and tissue growth. On the RxPepsDirect catalog it is described as a fragment that targets fat metabolism without growth effects.

According to PubMed, the supportive efficacy data is preclinical. A chronic-dosing study in obese mice (Heffernan et al., Endocrinology, 2001) showed that both human growth hormone and AOD-9604 reduced body weight and body fat and increased lipolytic sensitivity over 14 days of treatment, with effects linked to upregulation of beta-3 adrenergic receptor expression in fat cells (DOI). That is a real mechanism, but it is a mouse result.

The human reality check: AOD-9604 was advanced into clinical development as an anti-obesity candidate. A review of the obesity drug pipeline (Halford, Curr Opin Investig Drugs, 2006) listed it among compounds in development as a growth hormone fragment that increases adipose tissue breakdown (PubMed). It did not go on to demonstrate meaningful weight loss in human trials and was not brought to market as an obesity drug. In plain terms: the animal data is encouraging, the human efficacy data is thin to absent, and AOD-9604 should be treated as experimental.

4. Why neither alone addresses both compartments

The stack logic follows directly from the two evidence pictures above:

1. Tesamorelin acts on visceral fat, and largely spares subcutaneous fat. The Phase III data is explicit on this point: visceral adipose tissue dropped meaningfully while subcutaneous abdominal fat did not change to a clinically significant degree. That is a feature for visceral risk, but it means tesamorelin does not directly attack the pinchable layer.
2. AOD-9604 is marketed for the subcutaneous layer. Its proposed mechanism is direct fat-cell lipolysis, which would, in theory, address the compartment tesamorelin leaves alone.

Put together, the argument is that one molecule covers what the other misses. It is a clean story, and it is why prescribers and biohackers discuss the pairing. The weakness is equally clean: the molecule assigned to the subcutaneous compartment (AOD-9604) is the one without convincing human efficacy data. So the stack is only as strong as its weakest link, and that link is AOD-9604.

This is also why the RxPepsDirect catalog offers a pre-blended option, the Lean Stack, which combines AOD-9604, MOTs-C, tesamorelin, and ipamorelin in a single vial for patients who want a multi-pathway approach in one injection.

5. The combined protocol

When the two are run together, the design goal is dual-compartment coverage with a single daily subcutaneous injection routine. Tesamorelin is dosed in the evening to align with the body's natural nocturnal growth hormone surge, which is also when many patients report the best sleep response. AOD-9604 is typically dosed on a weekday schedule alongside it.

Both peptides on the RxPepsDirect catalog are filled and shipped pre-reconstituted by Optimal Balance Pharmacy, FedEx overnight, in a reusable cooled travel case. There is no mixing of bacteriostatic water at home. The patient draws the prescribed number of units and injects subcutaneously.

A note on the molecules being prescribed separately versus blended: some providers prescribe tesamorelin and AOD-9604 as two vials so each can be titrated independently; others use the single-vial Lean Stack for convenience. Which path fits depends on the provider's plan and the patient's tolerance.

6. Dosing

Dosing must come from the prescribing provider, but here are the reference figures that anchor the conversation.

An important honesty note on figures you may see elsewhere. Some stack write-ups cite a flat 2 mg of AOD-9604 plus 2 mg of tesamorelin daily. The 2 mg figure for tesamorelin matches the dose used in the Phase III trials. The 2 mg figure for AOD-9604 is far above the RxPepsDirect catalog starting dose of 0.24 mg and is not anchored to any human efficacy trial, since AOD-9604 has none that established a working dose. Do not assume a higher AOD-9604 number is better-evidenced; it is not. Use the dose your provider prescribes.

7. Sample 16-week protocol

This is an illustrative structure, not a prescription. It mirrors how providers commonly phase a body-composition peptide course around a reassessment point.

• Weeks 1 to 4 (ramp): Start both peptides at the catalog starting doses. Establish the evening injection habit and watch for early side effects such as injection-site reactions or fluid retention.
• Weeks 5 to 12 (steady state): Continue daily dosing on the 5-days-on schedule. This is the window where tesamorelin's visceral fat effect, which trials measured over 26 weeks, begins to accumulate. Pair with consistent diet and training.
• Weeks 13 to 16 (assess): Reassess waist measurement, body composition, and IGF-1 labs. The provider decides whether to continue, adjust, cycle AOD-9604 off for 2 to 4 weeks, or stop.

Because tesamorelin's benefit reverses when treatment stops, any patient continuing past 16 weeks should plan for an ongoing course with periodic monitoring rather than a one-and-done cycle.

8. Expected results by compartment

The honest summary: the visceral half of this stack is well supported in its studied population and plausibly transferable, while the subcutaneous half is speculative. A patient who responds well is most likely seeing tesamorelin's visceral effect plus the fat loss their diet and training would have produced anyway. Set expectations accordingly.

9. Diet and training pairing

No peptide overrides energy balance. Both tesamorelin and AOD-9604 are adjuncts that work best layered on top of the fundamentals, not as substitutes for them.

• Calorie deficit. Overall fat loss still requires eating fewer calories than you burn. The stack does not create a deficit; it is meant to shift where fat comes off and how the body partitions it.
• Protein and resistance training. Adequate protein and progressive resistance training protect lean mass during a deficit, which keeps the result a recomposition rather than just scale weight loss.
• Sleep. Tesamorelin's evening timing aligns with the nocturnal growth hormone pulse, and many patients report improved sleep, which itself supports body composition.

10. Side effects

Tesamorelin. In the Phase III trials the most common treatment-emergent events were injection-site reactions and effects typical of raising growth hormone: joint pain (arthralgia), headache, and peripheral fluid retention. Serious adverse events were uncommon (under 4 percent over 26 weeks), and glucose parameters did not change in a clinically meaningful way in the studied population. The arthralgia and fluid retention are the symptoms most patients actually notice.

AOD-9604. It is generally described as well tolerated, with injection-site reactions the main reported complaint, and the catalog notes it does not affect blood sugar or growth the way full growth hormone does. The honest caveat is that long-term human safety data is limited, which is a direct consequence of its thin clinical development history.

Both. Because both relate to the growth hormone axis, providers screen for and monitor relevant labs. Report new joint pain, swelling, vision changes, or numbness and tingling to your provider promptly.

11. Patient selection and contraindications

This stack is not for everyone, and the screening is the point of having a licensed provider involved.

Good candidates are generally adults with excess central (abdominal) fat, particularly a visceral pattern, who have a real diet and training base and realistic expectations about effect size.

Contraindications for the growth hormone-releasing component include:

• Active cancer or recent cancer history.
• Pituitary tumor or other pituitary disease.
• Pregnancy or breastfeeding.
• Uncontrolled diabetes or active diabetic retinopathy (discuss closely with the provider).

IGF-1 and a basic metabolic panel are useful baseline and monitoring labs. Patients with a cancer history should clear GH-axis therapy with their oncologist before starting.

12. How to get the stack

Both peptides are available through a licensed telehealth provider and a 503A compounding pharmacy. The process is straightforward:

1. Online intake. Complete a structured health history including cancer history, medications, and goals. No in-person clinic visit is required.
2. Provider review. A licensed RxPepsDirect provider reviews your intake, confirms candidacy, and screens for contraindications.
3. Prescription and fill. RxPepsDirect writes the prescription. Optimal Balance Pharmacy, a 503A compounding pharmacy, fills it, ships it pre-reconstituted by FedEx overnight in a reusable cooled travel case, and collects the medication payment directly.
4. Monitoring. Reassess body composition and IGF-1 at roughly 90 days to decide on continuing, adjusting, or stopping.

Two parties, two charges. RxPepsDirect bills a separate $39 medical visit fee for the provider review and prescription. The medication itself is billed by Optimal Balance Pharmacy, not by RxPepsDirect. On the current catalog, tesamorelin runs $100 per 15 mg vial and AOD-9604 runs $80 per 6 mg vial, with the pre-blended Lean Stack at $125 per vial. RxPepsDirect writes the prescription only and never dispenses, ships, or sells the medication.

Access: RxPepsDirect prescribes in 28 U.S. States. Eligibility is confirmed at intake based on the patient's state and the prescriber's licensure.